Efficacy and safety of olmesartan medoxomil in hypertension and its role in reducing the risk of dementia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a review of studies on the use of olmesartan medoxomil in hypertension. Most studies have shown that olmesartan medoxomil provides effective blood pressure control in patients with hypertension with a different cardiovascular risk profile with good tolerability. It was noted that olmesartan medoxomil has pleiotropic effects: vasoprotective, cardioprotective, nephroprotective, cerebroprotective, antiatherogenic, anti-inflammatory. The role of olmesartan medoxomil in the prevention (reduction of risk) of cognitive impairment or dementia has been established.

Full Text

Restricted Access

About the authors

T. Potupchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-1133-4447
SPIN-code: 8353-3513

Candidate of Medical Sciences

Russian Federation, Krasnoyarsk

O. Averyanova

Medical and diagnostic clinic "Computer Technology Medicine"

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0001-5523-2867
Russian Federation, Krasnoyarsk

K. Torgaeva

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0006-1223-4703
Russian Federation, Krasnoyarsk

V. Davidenko

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Email: potupchik_tatyana@mail.ru
ORCID iD: 0009-0001-9888-3520
Russian Federation, Krasnoyarsk

References

  1. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29 (9): 6117 [Kobalava J.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2024. Russian Journal of Cardiology. 2024; 29 (9): 6117 (in Russ.)]. doi: 10.15829/1560-4071-2024-6117
  2. Ложкина М.В., Коваленко Е.В., Арабидзе Г.Г. Современные возможности применения антагонистов рецепторов ангиотензина II в клинической практике. Международный журнал сердца и сосудистых заболеваний. 2020; 8 (26): 39–47 [Lozhkina M.V., Kovalenko E.V., Arabidze G.G. Modern possibilities of using angiotensin II receptor antagonists in clinical practice. International Journal of Heart and Vascular Diseases. 2020; 8 (26): 39–47 (in Russ.)].
  3. Tada Y., Yagi K., Uno M. et al. Improvement of plasma biomarkers in patients with hypertension and stroke after switching to olmesartan from other angiotensin receptor blockers. J Stroke Cerebrovasc Dis. 2015; 24 (7): 1487–92. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.015
  4. Jo S.H., Kang S.M., Yoo B.S. et al. A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study. J Clin Med. 2022; 11 (2): 350. doi: 10.3390/jcm11020350
  5. Zhang Z., Yang H., Guo H. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis. Int J Clin Pharm. 2024; 46 (5): 1034–43. doi: 10.1007/s11096-024-01755-5
  6. Tiwaskar M., Mehta K.K., Kasture P.J. A Review of Olmesartan-based Therapy in Targeting Effective Blood Pressure Control and Achieving Blood Pressure Goals. Assoc Physicians India. 2024; 72 (3): 75–8. doi: 10.59556/japi.72.0480
  7. Volpe M., Santolamazza C., Mastromarino V. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. High Blood Press Cardiovasc Prev. 2017; 24 (3): 243–53. doi: 10.1007/s40292-017-0216-1
  8. Lee D.W., Jung M., Wang H.W. et al. Systematic Review with Network Meta-Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients. Int J Hypertens. 2019; 2019: 9516279. doi: 10.1155/2019/9516279
  9. Kim B.J., Cha K.S., Cho W.H. et al. Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial. J Cardiovasc Pharmacol Ther. 2023; 28: 10742484231205204. doi: 10.1177/10742484231205204
  10. Buendia R., Zambrano M. Efficacy of olmesartan amlodipine in Colombian hypertensive patients (soat study). BMC Res Notes. 2017; 10 (1): 164. doi: 10.1186/s13104-017-2486-z
  11. Omboni S., Volpe M. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan. Adv Ther. 2019; 36 (2): 278–97. doi: 10.1007/s12325-018-0859-x
  12. Park S.J., Rhee S.J. Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective, Cohort Study. Adv Ther. 2020; 37 (8): 3500–14. doi: 10.1007/s12325-020-01404-z
  13. Okamura K., Yano Y., Takamiya Y. et al. Efficacy and safety of a combination antihypertensive drug (Olmesartan plus azelnidipine): "Issues with hypertension studies in real-world practice". Clin Exp Hypertens. 2020; 42 (5): 438–48. doi: 10.1080/10641963.2019.1693586
  14. Cui Z., Qiu Z., Cheng W. et al. Efficacy and safety of Olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study. J Clin Hypertens (Greenwich). 2024; 26 (1): 5–16. doi: 10.1111/jch.14700
  15. Дедов Д., Мукаилов Н., Евтюхин И. Комбинация амлодипина и аторвастатина в снижении риска кардиоваскулярных осложнений. Врач. 2013; 3:18–19 [Dedov D., Mukailov N., Evtyukhin I. Combination of amlodipine and atorvastatin in reducing the risk of cardiovascular complications. Vrach. 2013; 3:18–19 (in Russ.)].
  16. Redon J., Weber M.A., Reimitz P.E. et al. Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. J Clin Hypertens (Greenwich). 2018; 20 (2): 356–65. doi: 10.1111/jch.13183
  17. Kourlaba G., Gialama F., Tsioufis K. et al. A literature review to evaluate the clinical and economic value of Olmesartan for the treatment of hypertensive patients. Int J Cardiol. 2016; 221: 60–74. doi: 10.1016/j.ijcard.2016.06.115
  18. Omboni S., Volpe M. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. Cardiovasc Ther. 2018; 36 (6): e12471. doi: 10.1111/1755-5922.12471
  19. Albash R., Abdelbary A.A., Refai H. et al. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Int J Nanomedicine. 2019; 14: 1953–68. doi: 10.2147/IJN.S196771
  20. Бубнова М.Г. Блокатор рецепторов к ангиотензину II олмесартан в прерывании сердечно-сосудистого континуума: сосудо- и кардиопротективные, антиатеросклеротические и метаболические плейотропные эффекты (часть 2). CardioСоматика. 2015; 6 (1): 65–73 [Bubnova M.G. The angiotensin II receptor blocker olmesartan in interrupting the cardiovascular continuum: vascular and cardioprotective, antiatherosclerotic and metabolic pleiotropic effects (part 2). CardioSomatics. 2015; 6 (1): 65–73 (in Russ.)].
  21. Подзолков В.И., Писарев М.В. Блокаторы рецепторов ангиотензина с плейотропными свойствами: новый стандарт в управлении сердечно-сосудистыми рисками и лечении артериальной гипертензии. Рациональная фармакотерапия в кардиологии. 2017; 13 (3): 383–90 [Podzolkov V.I., Pisarev M.V. Angiotensin receptor blockers with pleiotropic properties: a new standard in the management of cardiovascular risks and treatment of hypertension. Rational pharmacotherapy in cardiology. 2017; 13 (3): 383–90 (in Russ.)]. doi: 10.20996/1819-6446-2017-13-3-383-390
  22. Shimoura H., Tanaka H., Matsumoto K. et al. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients. Heart Vessels. 2017; 32 (5): 584–90. doi: 10.1007/s00380-016-0904-0
  23. Карпов Ю.А., Руда М.М., Адырхаев З.А. и др. Рациональная фармакотерапия заболеваний сердца и сосудов. Compendium. М.: Литтерра, 2024 [Karpov Yu.A., Ruda M.M., Adyrkhaev Z.A. et al. Rational pharmacotherapy of heart and vascular diseases. Compendium. Moscow: Litterra, 2024 (in Russ.)]. doi: 10.33029/4235-0397-0-SSZ-2024-1-720
  24. Arao T., Okada Y., Mori H. et al. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocr J. 2013; 60 (5): 563–70. doi: 10.1507/endocrj.ej12-0326
  25. Li N.-C., Lee A., Whitmer R.A. et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010; 340: b5465. doi: 10.1136/bmj.b5465
  26. Liu J., Liu S., Tanabe C. et al. Differential effects of angiotensin II receptor blockers on Aβ generation. Neurosci Lett. 2014; 567: 51–6. doi: 10.1016/j.neulet.2014.03.030
  27. Wang J., Zheng B., Yang S. et al. Olmesartan Prevents Oligomerized Amyloid β (Aβ)-Induced Cellular Senescence in Neuronal Cells. ACS Chem Neurosci. 2021; 12 (7): 1162–9. doi: 10.1021/acschemneuro.0c00775
  28. Nakagawa T., Hasegawa Yu., Uekawa K. et al. Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II. Exp Gerontol. 2017; 87 (PtA): 108–12. doi: 10.1016/j.exger.2016.11.012
  29. Rodriguez-Ortiz C.J., Thorwald M.A., Rodriguez R. et al. Angiotensin receptor blockade with olmesartan alleviates brain pathology in obese OLETF rats. Clin Exp Pharmacol Physiol. 2023; 50 (3): 228–37. doi: 10.1111/1440-1681.13738

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russkiy Vrach Publishing House